CHARM Therapeutics

📍 London, United Kingdom🗓 Founded 2021👥 34 employees💰 Last funded Apr 2023
Biotechnology Research🌐 charmtx.com
Website LinkedIn
CHARMs lead program is a next-generation menin inhibitor for the treatment of acute myeloid leukemia (AML). Unlike first-generation menin inhibitors that rapidly lose potency due to menin resistance mutations, CHARMs candidates are specifically designed to maintain potency against all known clinical resistance mutations, potentially delivering the durable responses that patients desperately need.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
United Kingdom
1
Investor activity2021–2023 · investors recorded per year
202112022120231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in CHARM Therapeutics?
CHARM Therapeutics has 3 investors on record on gritt.io, including 3 early-stage backers.
When did CHARM Therapeutics last raise funding?
The most recent investment in CHARM Therapeutics recorded on gritt.io was in April 2023.
When was CHARM Therapeutics founded?
CHARM Therapeutics was founded in 2021.
What industry is CHARM Therapeutics in?
CHARM Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is CHARM Therapeutics based?
CHARM Therapeutics is headquartered in London, United Kingdom.